Quick Answer
Grace Therapeutics, Inc. reported Total Assets of $71.99 million for the year ending 2025.
- Grace Therapeutics, Inc. showed a decrease of -1.8% in Total Assets from 2024 to 2025.
- This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $20.14 million | Q3 2020: $13.83 million | Q4 2020: $30.30 million | Q2 2021: $60.45 million | Q3 2021: $119.80 million | Q4 2021: $114.23 million | Q2 2022: $124.93 million | Q3 2022: $120.91 million | Q4 2022: $116.80 million | Q2 2023: $73.03 million | Q3 2023: $78.21 million | Q4 2023: $76.19 million | Q2 2024: $69.72 million | Q3 2024: $65.35 million | Q4 2024: $61.22 million | Q1 2025: $71.99 million | Q2 2025: $69.81 million | Q3 2025: $66.58 million | Q4 2025: $68.49 million.
- Over the full 10 years of available data (2017 to 2025), Grace Therapeutics, Inc.'s Total Assets has grown by 173.0%.
- Historical annual values: Fiscal year 2025: $71.99 million | Fiscal year 2024: $73.30 million | Fiscal year 2023: $79.12 million | Fiscal year 2022: $128.62 million | Fiscal year 2021: $62.46 million | Fiscal year 2020: $22.85 million | Fiscal year 2019: $36.90 million | Fiscal year 2018: $22.96 million | Fiscal year 2017: $25.46 million | Fiscal year 2017: $26.37 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: